

KANEH BOSM BIOTECHNOLOGY INC.

810 – 675 West Hastings Street

Vancouver, BC V6B 1N2

Tel: 604.782.4191

NOT FOR DISSEMINATION IN THE UNITED STATES

NEWS RELEASE

March 6, 2017 – Vancouver, BC. - Kaneh Bosm BioTechnology Inc. (the “Company”) (CSE: KBB) closes \$50,000 Private Placement

Kaneh Bosm BioTechnology Inc. (KBB:CSE) (“Kaneh Bosm” or the “Company”) announces that the Company has closed its previously announced non-brokered private placement to 1,000,000 units for gross proceeds \$50,000 at a price of \$0.05 per unit.

Each unit consists of one common share of the Company and one common share purchase warrant. Each whole warrant is convertible into one common share at a price of \$0.065 per share and is exercisable for a period of two years.

The proceeds of the private placement will be used for general working capital.

On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.

“Rudy de Jonge”

Rudy de Jonge

CEO, Director

rudydejonge@hotmail.com

(604) 782-4191

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com